{"id":"NCT04052425","sponsor":"Incyte Corporation","briefTitle":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","officialTitle":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-20","primaryCompletion":"2021-03-18","completion":"2021-10-21","firstPosted":"2019-08-09","resultsPosted":"2022-09-21","lastUpdate":"2025-08-22"},"enrollment":330,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-segmental Vitiligo"],"interventions":[{"type":"DRUG","name":"Ruxolitinib cream","otherNames":["INCB018424 cream"]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Double-Blind Period: Ruxolitinib cream 1.5% BID","type":"EXPERIMENTAL"},{"label":"Double-Blind Period: Vehicle cream BID","type":"PLACEBO_COMPARATOR"},{"label":"Treatment-Extension Period: Ruxolitinib cream 1.5% BID","type":"EXPERIMENTAL"},{"label":"Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).","primaryOutcome":{"measure":"Percentage of Participants Achieving a â‰¥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24","timeFrame":"Baseline; Week 24","effectByArm":[{"arm":"Double-Blind Period: Ruxolitinib Cream 1.5% BID","deltaMin":29.8,"sd":null},{"arm":"Double-Blind Period: Vehicle Cream BID","deltaMin":7.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":57,"countries":["United States","Bulgaria","Canada","France","Germany","Italy","Poland","Spain"]},"refs":{"pmids":["40156697","36260792"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217471&parentIdentifier=INCB%2018424-306&attachmentIdentifier=d71091cc-485a-449d-bae2-c8c0e2a3e8e7&fileName=Incyte_PLS_INCB18424-306_Final.19_December_2023.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":[]}}